Latest News

Are there certain strategies that facilitate an alter ego-esque laser focus undeterred by distraction?

Catch up on a variety of FDA news in radiology from the past week.

Catch up on the top radiology content of the past week.

In addition to providing higher SNRs in vascular structures and parenchymal organs than energy-integrating detector CT, photon-counting CT enabled an approximately 30 percent reduction in volume CT dose index (CTDIvol) for patients with obesity, according to a new study.

Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.

Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.

The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.

In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.

The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.

In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.

The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.

In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.